Company · integrium-5e0116e0

Integrium

4 sourcescompanies-2026-11-14-0.1.0

Cite this record

ConductScience Library. Integrium. Companies, record integrium-5e0116e0. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/integrium-5e0116e0

On this page

Company

The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.

Name: Integrium
Trials: 26
As lead sponsor: 0
As collaborator: 26
Recruiting: 0
Active, recruiting or not: 0
Completed: 19
Stopped early, withdrawn or suspended: 6
Posted results: 11
Trials by phase: Phase 1 5, Phase 2 15, Phase 3 6, Phase 4 1
Drugs its trials test: 12
Comparisons calculated in its trials: 4
First trial registered: 2007-04-12
Last update: 2024-08-07

Source ClinicalTrials.gov

Pipeline12

The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.

Drug	Highest phase registered	Trials	Targets	Mechanism	In Drugs and targets	Source
AMLODIPINE	Phase 4	1	CACNA1C, CACNA1D, CACNA1F, CACNA1S	Voltage-gated L-type calcium channel blocker	https://conductscience.org/library/drugs/CHEMBL1491	Open Targets
HYDROCHLOROTHIAZIDE	Phase 4	1	SLC12A3	Thiazide-sensitive sodium-chloride cotransporter inhibitor	https://conductscience.org/library/drugs/CHEMBL435	Open Targets
OLMESARTAN MEDOXOMIL	Phase 4	1	AGTR1	Type-1 angiotensin II receptor antagonist	https://conductscience.org/library/drugs/CHEMBL1200692	Open Targets
ACLERASTIDE	Phase 3	3			https://conductscience.org/library/drugs/CHEMBL4297940	Open Targets
FENOFIBRATE	Phase 3	1	PPARA	Peroxisome proliferator-activated receptor alpha agonist	https://conductscience.org/library/drugs/CHEMBL672	Open Targets
PRAVASTATIN	Phase 3	1	HMGCR	HMG-CoA reductase inhibitor	https://conductscience.org/library/drugs/CHEMBL1144	Open Targets
INSULIN HUMAN	Phase 2	6	INSR	Insulin receptor agonist	https://conductscience.org/library/drugs/CHEMBL1201631	Open Targets
INSULIN LISPRO	Phase 2	3	INSR	Insulin receptor agonist	https://conductscience.org/library/drugs/CHEMBL1201538	Open Targets
OSILODROSTAT	Phase 2	2	CYP11B1	Cytochrome P450 11B1 inhibitor	https://conductscience.org/library/drugs/CHEMBL3099695	Open Targets
BGP-15	Phase 2	1			https://conductscience.org/library/drugs/CHEMBL4747845	Open Targets

1 to 10 of 12

See all 12 pipeline

Trials26

The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.

Trial	Title	Role	Phase	Status	Type	Participants	Start	Results first posted	Drugs	In Trials	Source
NCT05247528	Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects	Collaborator	Phase 1	Completed	Interventional	37	2021-12-20			https://conductscience.org/library/trials/NCT05247528	ClinicalTrials.gov
NCT04754334	A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus	Collaborator	Phase 3	Terminated	Interventional	346	2021-03-16			https://conductscience.org/library/trials/NCT04754334	ClinicalTrials.gov
NCT04618744	A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)	Collaborator	Phase 2	Completed	Interventional	32	2020-11-24	2024-08-07	INSULIN HUMAN	https://conductscience.org/library/trials/NCT04618744	ClinicalTrials.gov
NCT04606576	Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus	Collaborator	Phase 3	Terminated	Interventional	710	2020-12-15			https://conductscience.org/library/trials/NCT04606576	ClinicalTrials.gov
NCT04375436	Safety and Tolerability of NTRX-07 in Healthy Volunteers	Collaborator	Phase 1	Completed	Interventional	48	2019-10-10			https://conductscience.org/library/trials/NCT04375436	ClinicalTrials.gov
NCT04150107	A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes	Collaborator	Phase 2	Completed	Interventional	30	2019-10-17	2022-06-02	INSULIN HUMAN	https://conductscience.org/library/trials/NCT04150107	ClinicalTrials.gov
NCT03819881	A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy	Collaborator	Phase 1	Unknown status	Interventional	60	2018-10-10			https://conductscience.org/library/trials/NCT03819881	ClinicalTrials.gov
NCT03467932	A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus	Collaborator	Phase 2	Completed	Interventional	373	2018-05-29	2022-11-08		https://conductscience.org/library/trials/NCT03467932	ClinicalTrials.gov
NCT03290248	Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis	Collaborator	Phase 1/2	Completed	Interventional	71	2017-09-19	2022-11-25		https://conductscience.org/library/trials/NCT03290248	ClinicalTrials.gov
NCT03156361	21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus	Collaborator	Phase 2	Completed	Interventional	24	2017-05-18		INSULIN LISPRO	https://conductscience.org/library/trials/NCT03156361	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Conditions27

The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.

Condition	Trials
Hypertension	3
Type 2 Diabetes Mellitus	3
Diabetes Mellitus, Type 2	2
Diabetic Foot Ulcers	2
T2DM (Type 2 Diabetes Mellitus)	2
ADHF	1
Allergic Rhinitis	1
Allergic Rhinitis Due to Grass Pollen	1
Atopic Immunoglobulin E-Mediated Allergic Disorder	1
CHF	1

1 to 10 of 27Source ClinicalTrials.gov

See all 27 conditions

Partners21

The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.

Organization	Class	Trials shared	In Companies	Source
Oramed, Ltd.	Industry	9	https://conductscience.org/library/companies/oramed-ltd-181c1cb4	ClinicalTrials.gov
Diasome Pharmaceuticals	Industry	3	https://conductscience.org/library/companies/diasome-pharmaceuticals-57ff4080	ClinicalTrials.gov
Integra LifeSciences Corporation	Industry	3	https://conductscience.org/library/companies/integra-lifesciences-corporation-c2e64059	ClinicalTrials.gov
Great Lakes Drug Development, Inc.	Industry	2	https://conductscience.org/library/companies/great-lakes-drug-development-inc-a73f6a3c	ClinicalTrials.gov
Novartis	Industry	2	https://conductscience.org/library/companies/novartis-9328b082	ClinicalTrials.gov
Orange County Research Center	Other	2		ClinicalTrials.gov
AOBiome LLC	Industry	1	https://conductscience.org/library/companies/aobiome-llc-1364fe69	ClinicalTrials.gov
BHV Pharma	Industry	1	https://conductscience.org/library/companies/bhv-pharma-32c79613	ClinicalTrials.gov
Barc NV	Industry	1	https://conductscience.org/library/companies/barc-nv-4d701455	ClinicalTrials.gov
Daiichi Sankyo	Industry	1	https://conductscience.org/library/companies/daiichi-sankyo-b1cfab7a	ClinicalTrials.gov

1 to 10 of 21

See all 21 partners

Data dates

The date of each source this release read.

Sponsors and results posted: 2026-11-14; ClinicalTrials.gov
Trials' registrations: 2026-11-12; ClinicalTrials.gov
Drug links and targets: 2026-09-18; Open Targets
Comparisons: 2026-03-23; Trial comparisons

Sources 4

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL
ClinicalTrials.govNo license stated
Open TargetsCC0 1.0

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this company from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/companies/v1/integrium-5e0116e0

GET https://conductscience.org/api/companies/v1/integrium-5e0116e0/trials?page=2

API reference For AI assistants